A	B	C	D	E	F	G	H	I	J	K	L
1
2		Brand	Generic	Indication	MOA	Economics	Approval	IP
3		Trizivir	abacavir+lamivudine+zidovudine	HIV	NNRTI, NRTI	1	2000	6/18/12 COM, 11/16 Crystal
4		Lexiva	fosamprenavir	HIV	Protease	100%?	2003	2017 Prodrug patent
5		Bonviva		Osteoporosis	Bisphosphonate	Roche	2005	2012
6		Avandaryl	rosiglitazone/glimepiride	Diabetes	TZD+Sulfon	1	2005	Avandia+Amaryl				Old Drugs/Failures
7		Avandia	rosiglitazone	Diabetes	PPAR	1	1999	2012 settlement with Teva				Zofran: 2002-2009: 708m, 774m, 763m, 837m, 847m, 196m, 110m, 109m
8		Entereg		Post-Operative Ileus		ADLR	2008	2017?				otelixumab
9		Coreg CR	carvedilol	Hypertension	Alpha/Beta-Blocker	FLML	2007	Poor IP?				Rezonic/Zunrisa (casopitant) - CRL then discontinued 9/28/09.
10		Arixtra	fondaparinux	DVT/VTE	LMWH	1	2001	Complex Mixture?				Redona (DPP4) - safety discontinuation
11		Wellbutrin/XL	bupropion	Depression	SSRI	Sold to BVF	2003					GW274150 (iNOS)
12		Votrient	pazopanib	RCC	VEGF inhibitor	Sold to NVS	10/19/2009	NCE 2021: 7105530				GSK 773812 (atypical)
13		Arranon, Atriance	nelarabine	T-ALL, T-LBL		Sold to NVS	2005	Poor IP?				GSK 1838262 (migraine)
14		Tykerb	lapatinib	Trastuzumab-R BC	Kinase	1	3/1/2007	2020				almorexant: orexin antagonist insomnia candidate discontinued 1/11.
15		Arzerra	ofatumumab	CLL, FL, DLBCL	Anti-CD20	GEN DC	2009	Sued by ROG/BIIB, Antibody				GW-353,162/radafaxine
16		Promacta/Revolade	eltrombopag	ITP	Peptidomimetic	LGND	11/1/2008	NCE				Simplirix (Herpes Simplex Vaccine).
17		Requip	ropinirole	RLS	Dopamine Agonist	1	1997	2008 generic?				New Generation Flu (discontinued Q2 2010), possible code name 2186877A.
18		Lovaza		Triglycerides	Fish Oil	1	2004	Soon?				InterCell patch vaccine (travellers' diarrhea).
19		Combivir	lamivudine/zidovudine	HIV	Combination	1	1997	12/26/2009 30-month expiry
20		Paxil CR	paroxetine	Depression	SSRI	1	1992/1999	Generic?
21		Requip XL	RLS	Dopamine Agonist	1	7/1/2008		qd vs tid				Consumer
22		Trexima	Migraine	Triptan/NSAID	POZN	2008	Generic Components	Poor IP				Sensodyne is 11% of Consumer, 2% of Total Revenue.
23		Horizant	RLS	Gabapentin ER	XNPT	4/6/2011	Gabapentin	Carcinogenicity
24		Xyzal (levocetirizine)	Allergic Rhinitis		Japan Only;UCB
25		Relenza (zanamivir)	Influenza		Biota	1999
26		Havrix	HAV	Vaccine	1			Vaccine				Controversies
27		Prepandrix	H5N1 influenza	Vaccine	1		Vaccine					$750m Puerto Rico manufacturing facility
28		Pandemrix/Arepanrix	H1N1 influenza	Vaccine	1	2010						$3.4bn Avandia/US Attorney's DofCo.
29		Twinrix	HBV/HAV	Vaccine	1		Vaccine					$2.36bn settlements for PR, Avandia, Paxil and other.
30		Serevent (salmeterol)	Asthma	LABA	1	1994	Expired?					$400m for DofCo.
31		Imitrex (sumatriptin)	Migraine	Triptan	1	1995	Generic
32		Valtrex	Herpes	Antiviral	1	1995	2009 but generic approved					EM Acquisitions intelligent: Laboratorios Phoenix, Maxinutrition, Nanjing MeiRui, Dong-A, UCB portfolio, Aspen (A).
33		Lamictal (lamotrigine)	Epilepsy/Bipolar	Ion Channel	1	1994	Generic
34		Lamictal XR	Epilepsy	Ion Channel	1	5/29/2009	US Only
35		Avodart (dutasteride)	BPH	5-alpha reductase	1	2001	9/2013: 5998427 COM
36		Jalyn/Duodart (dutasteride/tamsulosin)	BPH	Combination	1	2010	9/2013: 5998427 COM
37		Allermist (fluticasone)	Allergic Rhinitis	Steroid	1	5/1/2007	2021
38
39
40
41		darapladib		Atherosclerosis	LP-PLA2	HGSI	III					Vaccines focus (A).
42		Syncria (albiglutide)	Type 2 Diabetes	GLP-1	HGSI	III	Byetta, Byetta LAR, Victoza					Selling research centers to Aptuit and Galapagos. (A).
43		GSK2118436 (dabrafenib)	Melanoma	BRAF	1	Filed	Roche					Sirtris acquisition (F).
44		IDX899	HIV	NNRTI	IDIX	II						Legal strategy (D).
45		firategrast ('699)	Multiple Sclerosis	VLA4	Tanabe?	II	Daiichi					Advair life-cycle management is brilliant (A).
46		681323 (losmapimod)	COPD, CV	p38 kinase	1	II						Poor licensing decisions or defensive maneuvers? Almorexant, Intercell (C-).
47		597599+parox, vestipitant	Depression		1	II
48		1349572	HIV	Integrase	Shionogi	III	MRK/GILD
49		Herpes Zoster Vaccine	Shingles	Vaccine	1	III
50		NicVax	Nictoine Addiction	Vaccine	NABI	III
51		rilapladib	Atherosclerosis	LP-PLA2	HGSI	II
52		2402968/PRO051	Duchenne Muscular Dystrophy	Antisense	?	II
53		XL880 (foretinib)	HCC	C-MET/VEGFR	EXEL	II
54		GSK2402968	DMD	Exon 51 skipper	Prosensa	III
55		1362885	Type 2 Diabetes	Glycogen Phosphorylase	1	II
56		1292263	Type 2 Diabetes	GPR119 agonist	1	II
57		557296	Premature Ejaculation	Oxytocin	1	II
58		221149 (retosiban)	Pre-Term Labour	Oxytocin	1	II
59
60
61
62			2011: submit ezogabine CR.
63			2012: File Relovair.
64			2012: MAGE data.
65
66			September 10 2006: DREAM results for Avandia in pre-diabetics
67			May 1 2007: AdCom for Advair
68			4/15/2008: Trexima PDUFA
69			7/10/2008: Lamictal XR response submitted.
70			Q2 2008: Advair COPD PDUFA
71			2008: Acquires Sirtris.
72			1/23/09: Acquires UCB EM products for 515GBP.
73			5/29/09: Lamictal XR approved.
74			6/6/09: Shenzhen Neptunus deal for flu vaccines in China.
75			6/15/09: RDY emerging markets deal.
76			7/2/09: Acquires BMY Lebanon/Jordan business for $23m.
77			7/22/09: Acquires Stiefel for $3.3bn.
78			10/6/09: Priorix MMR Chinese deal.
79			12/1/09: Completes Aspen transaction.
80			12/2009: Purchases Algerian drug company for $38m.
81			12/2009: NovaMin acquisition for 87m pounds.
82			3/2010: Acquires 25% of JCR Pharma (Japan).
83			5/2010: Acquires 10% of Dong-A for GBP74m.
84			6/2010: Acquires Phoenix Labs in Argentina for $250m.
85			12/7/10: Acquires Nanjing MeiRui Pharmaceuticals for $70m.
86			12/13/10: Acquires Maxinutrition for GBP162m.
87			12/19/10: German Federal register notes Chiesi's price of 50% discount to Advair.
88			1/17/11: $3.4bn USD legal charge. Afer tax of GBP1.8bn.
89
90
91
92
93
94
95
96
97
98
99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
131
132
133
134
135
136
137
138
139
140
141
142
143
144
145
146
147
148			Results announcement for the fourth quarter 2008
149			GSK’s paediatric pneumococcal candidate vaccine Synflorix™ receives positive opinion in Europe
150			GlaxoSmithKline receives European Commission approval to market alli® (orlistat 60mg)
151			GSK and Xenoport resubmit new drug application for Solzira™ in restless legs syndrome
152			GlaxoSmithKline and Archemix form strategic alliance to develop aptamers to treat inflammatory diseases
153			GlaxoSmithKline to cease providing corporate political contributions
154			GlaxoSmithKline extends tender offer for Genelabs Technologies, Inc.
155			Two new studies in the New England Journal of Medicine show malaria vaccine candidate advancing in Africa
156			GSK and Neptunus sign cooperation agreement to form joint venture for the co-development of flu vaccines in China, Hong Kong and Macau
157			Cervarix, GSK’s cervical cancer vaccine, wins tender for Dutch national immunisation programme
158			GlaxoSmithKline and AFFiRiS sign an exclusive licence and option agreement for therapeutic Alzheimer’s disease candidate vaccines
159			Results announcement for the third quarter 2008
160			GlaxoSmithKline to acquire the leading dry mouth brand, Biotene
161			GSK’s Emerging Markets strategy advances with acquisition in Egypt
162			GSK responds to NICE’s second technology appraisal consultation document on the use of Tyverb, in combination with capecitabine, for women with previously treated advanced or metastatic breast cancer
163			LF Elimination programme treats over half billion people and protects millions more from debilitating disease
164			GSK update on FDA review of Promacta® (eltrombopag)
165			New data for GlaxoSmithKline’s pre-pandemic H5N1 influenza vaccine, Prepandrix™, show administration flexibility for pandemic planning
166			GSK and Xenoport announce submission of new drug application requesting FDA approval of Solzira™ for Restless Legs Syndrome
167			Tyverb® demonstrates encouraging results in Phase II study in advanced head and neck cancer
168			ESMO 2008 - GlaxoSmithKline to present encouraging new data supporting late stage development programme
169			GlaxoSmithKline and Cellzome announce major strategic alliance
170			GlaxoSmithKline and Valeant Pharmaceuticals announce worldwide collaboration agreement for retigabine
171			GlaxoSmithKline and the Harvard Stem Cell Institute announce a unique collaboration to enable the discovery of new medicines
172			Results announcement for the second quarter 2008
173			GSK enters transformational agreement with Aspen to drive growth in emerging markets
174			GSK receives BITC CommunityMark for global community programmes
175			GlaxoSmithKline responds to FDA on Cervarix® and plans to submit final study data for approval
176			Cervarix™, GSK’s cervical cancer vaccine, wins tender for UK national immunisation programme
177			GlaxoSmithKline responds to Government announcement on the PPRS
178			GlaxoSmithKline and Mpex Pharmaceuticals form alliance to develop novel efflux pump inhibitors for use against serious gram-negative infections
179			Revolade® (eltrombopag) data presented at EHA: updated data for EXTEND plus new data for REPEAT and DELPHI studies
180			GlaxoSmithKline receives marketing authorisation in the EU for Tyverb® (lapatinib), the first oral targeted therapy for ErbB2-positive breast cancer
181			GlaxoSmithKline acquires Sirtris Pharmaceuticals, Inc., a world leader in sirtuin research and development
182			GlaxoSmithKline and Boston’s Immune Disease Institute put scientists head-to-head in race for new discoveries
183			GlaxoSmithKline successfully completes tender offer for shares of Sirtris Pharmaceuticals
184			New data offer insights into the potential role for Tykerb® / Tyverb® (lapatinib) in non-cytotoxic chemotherapy-based treatment regimens
185			New data on MAGE-A3 cancer immuno therapy support novel options of treating non-small cell lung cancer and melanoma
186			GlaxoSmithKline announces new drug application and Phase III results for Rezonic™ / Zunrisa™ (casopitant)
187			GlaxoSmithKline plc - results of AGM
188			First pre-pandemic vaccine approved to help protect against pandemic influenza
189			GSK announces results of first Phase III trial evaluating Tykerb®/Tyverb® (lapatinib) plus Herceptin® (trastuzumab)
190			The battle against obesity: European experts and pharmacists call for an increased role for pharmacy
191			Scientists publishing in Nature call for the diversification of antiviral stockpiles in preparation for an influenza pandemic
192			Cervarix™ provides longest duration of sustained neutralising antibodies reported for any vaccine against HPV 16 and 18 to date
193			GlaxoSmithKline commences tender offer to acquire Sirtris Pharmaceuticals
194			FDA approves Advair 250/50 for reduction of exacerbations in patients with COPD
195			GSK announces changes to Corporate Executive Team
196			GlaxoSmithKline awards £300,000 to community health charities in recognition of their work
197			GlaxoSmithKline's Volibris (ambrisentan) receives authorisation from the European Commission for the treatment of Functional Class II and III Pulmonary Arterial Hypertension
198			GSK receives positive opinion for conditional approval of new oral breast cancer treatment, Tyverb (lapatinib)
199			Results announcement for the first quarter 2008
200			GlaxoSmithKline to acquire Sirtris Pharmaceuticals, a world leader in 'Sirtuin' research and development
201			GlaxoSmithKline gains approval for co-administration of Avodart® (dutasteride) with tamsulosin for the treatment of benign prostatic hyperplasia under the European Mutual Recognition Procedure
202			GlaxoSmithKline reports further progress of oncology portfolio
203			GlaxoSmithKline and Regulus Therapeutics form strategic alliance to develop microRNA targeted therapeutics to treat inflammatory diseases
204			Treximet (sumatriptan and naproxen sodium) tablets approved by FDA for acute treatment of migraine
205			GlaxoSmithKline confirms receipt of FDA letter on regulatory reporting
206			FDA approves Rotarix [Rotavirus Vaccine, live, oral], the first vaccine licensed to complete the rotavirus immunisation series by four months of age
207			Tyverb (lapatinib) European regulatory update
208			Phase III study of Bosatria (mepolizumab) showed disease control with reduced corticosteroid use in hypereosinophilic syndrome
209			FDA grants Priority Review For Promacta / Revolade (Eltrombopag)
210			Update on GSK's malaria treatments: Dacart and Lapdap
211			XenoPort and GlaxoSmithKline report positive top-line results of final pivotal trial of XP13512/GSK1838262 for restless legs syndrome
212			GlaxoSmithKline statement: Public Library of Science Medicine article on antidepressant medicines
213			GlaxoSmithKline and Theravance announce expansion of the Horizon programme with start of large Phase 2B study of LABA in COPD patients
214			GSK's Volibris (ambrisentan) receives EMEA positive opinion for approval to treat class II and II pulmonary arterial hypertension (PAH)
215			New price reductions for GSK antiretrovirals in the world's poorest countries
216			Novel anti-CD20 monoclonal antibody ofatumumab demonstrates anti-tumour responses in patients with relapsed/refractory B-cell chronic lymphocytic leukaemia
217			FDA extends review of NDA for Entereg® (alvimopan)
218			Full-year results announcement 2007
219			GlaxoSmithKline responds to findings in ACCORD study
220			GlaxoSmithKline receives EMEA positive opinion for the approval of Hycamtin® (topotecan) hard capsules for the treatment of relapsed small cell lung cancer
221			GlaxoSmithKline and Amira Pharmaceuticals enter global agreement for FLAP inhibitor programme
222			GlaxoSmithKline files pneumococcal paediatric vaccine in the EU
223			GlaxoSmithKline welcomes European guidance that stockpiling more than one antiviral would be useful in preparing for a flu pandemic
224			GlaxoSmithKline and Synta announce elesclomol granted US orphan drug designation by the FDA
225			GSK appoints Lon Cardon to focus genetics on new disease targets
226			GSK and MRC to identify new therapeutic targets and biomarkers from genetic association studies
227			GlaxoSmithKline and TB Alliance renew tuberculosis drug discovery programme
228			GlaxoSmithKline and Medicines For Malaria Venture announce new collaboration to investigate novel antimalarial compounds
229			GlaxoSmithKline to revise Avandia® (rosiglitazone maleate) label in Europe following assessment by CHMP
230			GlaxoSmithKline and Adolor report favourable FDA Advisory Committee meeting for Entereg® (alvimopan) for the management of postoperative ileus in bowel resection
231			New allergic rhinitis treatment Avamys™ approved in Europe
232			GlaxoSmithKline and XenoPort report positive top-line results of second phase 3 restless legs syndrome trial for XP13512/GSK1838262
233			GlaxoSmithKline and Theravance announce start of large Phase 2B ICS and LABA studies for asthma in the Horizon programme
234			First head-to-head study comparing common treatments for patients with COPD shows quality of life and survival benefits for patients treated with Seretide
235			GlaxoSmithKline files for FDA approval of Promacta/Revolade (eltrombopag) to be the first oral platelet growth factor for rare blood disorder
236			GlaxoSmithKline and Santaris Pharma enter global R&D alliance to discover, develop and commercialise RNA antagonists as novel antivirals
237			GlaxoSmithKline completes acquisition of Reliant Pharmaceuticals
238			GlaxoSmithKline receives FDA ‘complete response’ letter for cervical cancer vaccine
239			GlaxoSmithKline announces data on Tykerb® (lapatinib) plus capecitabine for the treatment of HER2-positive breast cancer brain metastases
240			GlaxoSmithKline, via its Centre Of Excellence for External Drug Discovery, exercises its options to further develop and commercialise Exelixis’ anti-cancer C-Met inhibitior XL880
241			GlaxoSmithKline presents innovative neuroscience pipeline
242			GlaxoSmithKline responds to JAMA article on the ICES thiazolidinediones and cardiovascular outcomes in older patients with diabetes
243			GlaxoSmithKline receives decision from US FDA on Requip® XL™
244			Long-term safety and efficacy data on Promacta™ (eltrombopag) presented at American Society of Hematology Annual Meeting
245			GlaxoSmithKline and OncoMed Pharmaceuticals form strategic alliance to develop cancer stem cell antibody therapeutics
246			GlaxoSmithKline and Galapagos enter strategic alliance to develop novel antibacterials and antivirals
247			GlaxoSmithKline announces appointments to the Board of Directors
248			GSK’s continued commitment to fighting HIV/AIDS results in approval of new formulations of three medicines for the treatment of children
249			Statement from GlaxoSmithKline: publication of update regarding thiazolidinediones to treatment guidelines for the management of type 2 diabetes mellitus by the European Association for the Study of Diabetes (EASD) and the American Diabetes Association (ADA)
250			GSK response to Nature Medicine article on rosiglitazone and bone in mice
251			GSK statement on US Food and Drug Administration Pediatric Advisory Committee recommendations regarding salmeterol
252			GlaxoSmithKline obtains exclusive US OTC marketing rights to Mevacor® (lovastatin) from Merck & Co., Inc.
253			New data published in The Lancet show GSK's rotavirus vaccine Rotarix offers sustained and broad protection against all common circulating rotavirus types
254			GlaxoSmithKline to acquire Reliant Pharmaceuticals
255			GlaxoSmithKline and Genmab initiate ofatumumab rheumatoid arthritis Phase III programme
256			GSK and the European Foundation for the Study of Diabetes (EFSD) commit €1 million to diabetes research in Europe
257			GlaxoSmithKline revises US labeling for Avandia
258			Prometheus to acquire Lotronex® from GlaxoSmithKline
259			GlaxoSmithKline initiates trials of Promacta®/Revolade™ (eltrombopag) to investigate the potential to aid hepatitis C patients in achieving sustained virological response
260			New innovation grants boost malaria advocacy efforts in Africa
261			Fabre Kramer Pharmaceuticals receives decision from FDA on gepirone ER for major depressive disorder
262			Results announcement for the third quarter 2007
263			GlaxoSmithKline and Tolerx form worldwide collaboration for development and commercialisation of novel medication
264			New allergic rhinitis treatment Avamys™ receives positive opinion in Europe
265			European Medicine Agency (EMEA) confirms positive Avandia benefit risk assessment
266			New Lancet study: Malaria vaccine candidate has promising safety, tolerability profile in infants
267			GSK receives approval for Hycamtin® (topotecan) capsules for the treatment of relapsed small cell lung cancer
268			GlaxoSmithKline and Synta Pharmaceuticals announce development and commercialisation collaboration for STA-4783 in oncology
269			GlaxoSmithKline appoints Andrew Witty CEO designate
270			GlaxoSmithKline and Anacor Pharmaceuticals form alliance to develop systemic antivirals and antibiotics based on boron chemistry
271			GSK seeks prequalification for Cervarix™ from the World Health Organization after obtaining marketing approval in Europe
272			GSK applies for licence to market OTC weight loss product In Europe
273			GSK submits Cervarix licence application to Japan's health authorities
274			GlaxoSmithKline plc announces change to the Board of Directors
275			GlaxoSmithKline helps form the Serious Adverse Events Consortium
276			Cervarix, GSK's cervical cancer vaccine, approved In Europe
277			GSK receives decision from FDA on Lamictal®XR™ Extended-Release Tablets
278			GlaxoSmithKline and Sepracor Inc. announce international alliance for commercialisation of Lunivia
279			GlaxoSmithKline responds to JAMA articles
280			Study shows combination therapy incorporating Avodart® and tamsulosin provides continuous symptom improvement over two years
281			GlaxoSmithKline's Arixtra® receives European authorisation for the treatment of acute coronary syndromes
282			FDA accepts for review complete response to approvable letter for Entereg® (alvimopan) for POI
283			GlaxoSmithKline receives approval for Atriance® (nelarabine) in Europe for the treatment of difficult-to-treat leukaemias and lymphomas
284			GlaxoSmithKline signs contract for its pandemic flu vaccine with UK Government
285			GlaxoSmithKline's application for Rotarix® is accepted for review by the FDA
286			GlaxoSmithKline updates prescribing information for Avandia in the US
287			GSK gives consent under Canada's Access to Medicines Regime for generic version of HIV/AIDS medicine for use in Rwanda
288			GSK receives decision from FDA on Advair 500/50 for COPD
289			GlaxoSmithKline receives new HHS order for H5N1 bulk antigen
290			FDA issues second approvable letter for Trexima™
291			GSK comments on UK Government announcement to renegotiate current Pharmaceutical Pricing and Regulation Scheme agreement
292			GlaxoSmithKline presents Avandia data to FDA
293			Pharmetrics epidemiology study
294			FDA Advisory Panel votes 22 to 1 for Avandia® to remain available to patients in the US
295			GlaxoSmithKline statement in diabetes care study thiazolidinediones and heart failure: a teleo-analysis [1]
296			GlaxoSmithKline and Targacept form alliance in therapeutics for CNS-related disorders
297			New head-to-head study comparing Lexiva® and atazanavir show similar efficacy and lipid changes
298			Results announcement for the second quarter 2007
299			GSK's cervical cancer candidate vaccine Cervarix™ receives positive opinion in Europe for prevention of cervical cancer
300			GSK responds to online review of rosiglitazone by The Cochrane Collaboration
301			GSK receives extended licence indication for Seretide in Europe following submission of TORCH data for COPD
302			Largest cervical cancer vaccine efficacy trial shows Cervarix™ provides excellent protection against lesions caused by most common cancer-causing virus types
303			GlaxoSmithKline's Arixtra® (fondaparinux sodium) receives positive opinion in Europe for the treatment of acute coronary syndromes
304			New data show patients treated with Avandia® (rosiglitazone maleate) incurred lower medical costs and used fewer healthcare resources when compared to patients treated with sulphonylureas
305			GlaxoSmithKline's Atriance (nelarabine) receives positive opinion in Europe for the treatment of rare, difficult to treat leukaemias and lymphomas
306			GlaxoSmithKline expects to launch up to five major new medicines for oncology in next three years
307			GlaxoSmithKlline and Genmab present positive Phase II results with ofatumumab in patients with rheumatoid arthritis (RA)
308			GlaxoSmithKline, Imperial College London, and The Medical Research Council officially open the UK's world-leading Clinical Imaging Centre
309			GlaxoSmithKline to make unprecedented vaccine donation to WHO pandemic flu stockpile
310			GlaxoSmithKline's application for DTaP-IPV vaccine is accepted for review by the FDA
311			alli™ - the OTC weight loss product - on shelves nationwide in the US later this week
312			FDA grants priority review for oral formulation of HYCAMTIN (topotecan) to treat relapsed small cell lung cancer
313			GlaxoSmithKline and Adolor update alvimopan (Entereg/Entrareg) development programme
314			Pivotal phase III trial showed RevoladeTM (eltrombopag) raised platelet counts and reduced bleeding in patients with chronic ITP
315			Newly published data from large study support cardiovascular safety of Avandia (rosiglitazone maleate)
316			Statement of Moncef Slaoui, PhD, Chairman Research & Development, GlaxoSmithKline
317			Encouraging clinical activity of GSK's novel cancer immunotherapeutic confirmed in phase II study in patients with most common form of lung cancer
318			Cervarix, the GSK cervical cancer candidate vaccine, provides sustained immune response in 100 per cent of women up to 55 years of age
319			Interim data from RECORD study show no significant difference between Avandia and standard therapy in risk of cardiovascular hospitalization or death
320			GlaxoSmithKline response to New England Journal of Medicine editorials
321			GSK's pazopanib shows positive results in patients with advanced renal cell carcinoma, ovarian cancer and soft tissue sarcoma
322			Eight-year long-term data demonstrate prolonged overall survival and length of disease remission with BEXXAR
323			GlaxoSmithKline reports positive new data on Tykerb (lapatinib) at the 2007 American Society of Clinical Oncology (ASCO) annual meeting
324			GlaxoSmithKline announces Altargo approved in Europe for treatment of Impetigo and other skin infections
325			GlaxoSmithKline honours cancer research pioneer Gianni Bonadonna with new ASCO award and fellowship
326			Data affirms Avandia (rosiglitazone maleate) cardiovascular safety profile
327			Retrospective observational study shows combination vaccines may improve vaccination coverage rates in infants
328			GlaxoSmithKline launches Chinese R&D centre with appointment of head in Shanghai
329			GlaxoSmithKline announces Swiss approval of Tyverb®, a new oral treatment for advanced breast cancer
330			GlaxoSmithKline plc - results of AGM
331			alli™ debuts through the alli Experience
332			Cervarix™ is approved in Australia for females 10-45 years old
333			GlaxoSmithKline responds to NEJM article on Avandia
334			GlaxoSmithKline strongly defends its record on Avandia
335			Sally Field addresses members of Congress about osteoporosis during national osteoporosis awareness month
336			GlaxoSmithKline's Hib-MenCY-TT combination vaccine meets phase II study endpoints of immunogenicity and safety compared to licensed vaccines
337			Cervarix® data show that higher levels of antibodies in the bloodstream correlate to higher levels in cervico-vaginal secretions
338			Fabre-Kramer refiles gepirone ER with the FDA for the treatment of major depressive disorder
339			GlaxoSmithKline's investigational DTaP-IPV combination vaccine shown to be immunogenic and well-tolerated in Phase III clinical trial
340			GlaxoSmithKline supports World Health Organization efforts to strengthen global pandemic preparedness plans
341			Trexima™ (sumatriptan/naproxen sodium) provided relief of both traditional and non-traditional migraine symptoms
342			FDA Advisory Committee finds substantial evidence to support Advair 500/50 in reducing COPD exacerbations
343			New data shows once a day Lamictal® XR™ is effective in treating patients with partial seizures
344			GlaxoSmithKline and Wellcome Trust announce partnership to target drug-resistant hospital infections
345			FDA approves once-daily Veramyst (fluticasone furoate) Nasal Spray for treatment of seasonal and year-round allergy symptoms in adults and children as young as two years
346			Results announcement for the first quarter 2007
347			GlaxoSmithKline receives Japanese approval for two major new product opportunities: Seretide/Advair and Arixtra
348			Community health charities receive £265,000 in recognition of their work from GlaxoSmithKline
349			Cervarix®, GSK cervical cancer candidate vaccine, demonstrates 100 percent protection against precancerous lesions caused by cancer-causing human papillomavirus types 16 & 18 for more than five years
350			GSK initiates repeat dosing study of its novel oral platelet growth factor, eltrombopag, in ITP
351			GSK announces FDA approval of Altabax (retapamulin ointment), 1%
352			GSK and Adolor announce preliminary results from phase 3 Safety study of Alvimopan (Entereg/Entrareg)
353			Once daily, extended-release ropinirole improves Parkinson's symptoms in patients not optimally controlled with levodopa
354			Trexima (sumatriptan/naproxen sodium) superior efficacy data published in JAMA
355			GlaxoSmithKline KK seeks approval in Japan for lapatinib, a new treatment for breast cancer
356			FDA approves accelerated dosing schedule for GlaxoSmithKline's Twinrix
357			GlaxoSmithKline files meningococcal conjugate vaccine
358			GlaxoSmithKline submits biologics license application to US Food and Drug Administration for Cervarix
359			GlaxoSmithKline appoints Zhi Hong to head infectious-diseases research centre
360			New study indicates nicotine patches may be safe for helping patients with coronary artery disease to quit smoking
361			GlaxoSmithKline announces Altargo receives positive opinion in Europe for treatment of impetigo and other skin infections
362			GSK giving figures exceed £300 million for fourth year running: medicines for Lymphatic Filariasis elimination valued at £16 million
363			GSK announces nationwide availability of once-a-day Coreg CR for the treatment of three key cardiovascular conditions
364			FiberChoice plus multivitamins issues allergy alert
365			FDA approves Tykerb (lapatinib) in combination with Xeloda (capecitabine) for the treatment of advanced or metastatic breast cancer in women who have progressed on prior therapy
366			New JACC analysis details cardiovascular protective benefits of carvedilol in heart failure patients
367			New studies indicate GSK's pre-pandemic influenza vaccine can protect against different strains of H5N1
368			Study published in New England Journal of Medicine: Vaccine 95.5% effective against neglected hepatitis E
369			New data show fluticasone furoate nasal spray effectively treated nasal symptoms of allergic rhinitis
370			GSK initiates first global Phase III study of Tykerb (lapatinib) in head and neck cancer
371			Landmark study shows important benefits of Seretide treatment for patients with fatal lung disease, COPD
372			GlaxoSmithKline acquires exclusive rights to over-the-counter orlistat for markets outside the US from Roche Group
373			OFT market study into the Pharmaceutical Price Regulation Scheme
374			GlaxoSmithKline successfully completes tender offer for shares of Praecis Pharmaceuticals
375			GlaxoSmithKline Diseases of the Developing World ad campaign receives industry award
376			WHO awards prequalification status to GSK rotavirus vaccine
377			GlaxoSmithKline and Human Genome Sciences announce initiation of Phase 3 clinical trial of Lymphostat-B in systemic lupus erythematosus
378			GlaxoSmithKline offers new tools to help patients get free medicines
379			GlaxoSmithKline plc announces change to the Board of Directors
380			GlaxoSmithKline commends $1.5 billion advance market commitment for pneumococcal vaccines
381			Full-year results announcement 2006
382			GlaxoSmithKline and XenoPort announce agreement on late-stage compound for RLS and neuropathic pain
383			GlaxoSmithKline and Fabre-Kramer Pharmaceuticals enter global agreement for new treatment of major depressive disorder
384			FDA approves alli (orlistat 60 mg capsules) over-the-counter
385			GlaxoSmithKline accepts shares in tender offer for shares of Praecis Pharmaceuticals and commences subsequent offering period
386			GlaxoSmithKline receives approvable letter for new indications for Arixtra (fondaparinux sodium) injection
387			Valtrex (valacyclovir) - US patent litigation update
388			GlaxoSmithKline statement - BBC Panorama - 29 January 2007
389			GlaxoSmithKline files its new pre-pandemic influenza vaccine in Europe
390			GlaxoSmithKline initiates head-to-head study of cervical cancer vaccines
391			GlaxoSmithKline awarded $63 million HHS contract for pandemic vaccine research and development: Company begins government and retail shipments of its antiviral Relenza
392			GlaxoSmithKline receives first European approval for Wellbutrin XR
393			GlaxoSmithKline commences tender offer to acquire Praecis Pharmaceuticals